Sidley Austin

This Practice Note has been archived and is not maintained. It discusses the regulatory implications of the coronavirus (COVID-19) pandemic for the UK and European life sciences industry. It provides guidance as to the response of UK and EU regulators in the areas of clinical trials, inspections and the continuity of supply in medicinal products and medical devices, as well as the postponement of implementation of the Medical Devices Regulation (MDR). It also summarises key research and development (R&D) initiatives at a UK and EU level and European Commission guidance on the collection and transfusion of convalescent COVID-19 plasma.

The Payment Systems Regulator (PSR) was established under the Financial Services (Banking Reform) Act 2013 (FS(BR)A 2013) and became fully operational in April 2015. This Practice Note provides further details of the Payment Systems Regulator’s statutory powers and duties under FS(BR)A 2013, as well as its concurrent competition powers under the Competition Act 1998 and Enterprise Act 2002.

The Payment Systems Regulator (PSR) was established under the Financial Services (Banking Reform) Act 2013 (FS(BR)A 2013) and became fully operational in April 2015. This Practice Note provides details of the PSR’s approach to supervising payment systems as set out in the PSR’s policy statement (PS 15/1) as well as its concurrent competition guidance and approach to monitoring and enforcing the assimilated Interchange Fee Regulation (Regulation (EU) 2015/751) (UK IFR). It also provides information on general and specific directions issued by the PSR, market reviews and super-complaints.